Inhibition of surface-induced platelet activation by nitric oxide

M. K. Sly, M. D. Prager, R. C. Eberhart, Michael E Jessen, Padmakar V Kulkarni

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

This study was undertaken to determine whether the nitric oxide/platelet cyclic guanosine monophosphate (NO/cGMP) pathway might be used to reduce platelet activation by artificial surfaces. Because serotonin release (SR) is a platelet activation indicator, rabbit platelets in their own plasma (PRP) were labeled with 3H-serotonin. Labeled PRP was incubated with glass beads for 5-10 min. at 37°C with gentle agitation, and SR was measured. PRP pretreatment with NO gas or nitroprusside + N-acetylcysteine inhibited SR 50%. Dose response studies indicate the existence of an optimal NO concentration above which its inhibitory effect is diminished. The guanylate cyclase inhibitor methylene blue attenuates the NO effect, implicating cGMP in NO mediated inhibition of surface induced platelet activation. Adult pigs were supported on a membrane oxygenator in an in vitro model of cardiopulmonary bypass (CPB). Introduction of NO gas into the oxygenator sweep gas at 500 ppm reduced platelet adherence to the oxygenator surfaces, increased circulating platelet counts, and decreased the rate of platelet aggregation (whole blood impedance platelet aggregometry) compared with the results of the control animals. Indications of NO toxicity were seen when the NO flow rate was increased to 1,000 ppm. These studies support the hypothesis that NO reduces platelet activation by artificial surfaces in clinical devices.

Original languageEnglish (US)
JournalASAIO Journal
Volume41
Issue number3
StatePublished - 1995

Fingerprint

Nitric oxide
Platelet Activation
Platelets
Serotonin
Nitric Oxide
Blood Platelets
Chemical activation
Oxygenators
Gases
Membrane Oxygenators
Guanylate Cyclase
Methylene Blue
Cyclic GMP
Acetylcysteine
Nitroprusside
Cardiopulmonary Bypass
Electric Impedance
Platelet Count
Platelet Aggregation
Glass

ASJC Scopus subject areas

  • Biophysics
  • Bioengineering

Cite this

Sly, M. K., Prager, M. D., Eberhart, R. C., Jessen, M. E., & Kulkarni, P. V. (1995). Inhibition of surface-induced platelet activation by nitric oxide. ASAIO Journal, 41(3).

Inhibition of surface-induced platelet activation by nitric oxide. / Sly, M. K.; Prager, M. D.; Eberhart, R. C.; Jessen, Michael E; Kulkarni, Padmakar V.

In: ASAIO Journal, Vol. 41, No. 3, 1995.

Research output: Contribution to journalArticle

Sly, MK, Prager, MD, Eberhart, RC, Jessen, ME & Kulkarni, PV 1995, 'Inhibition of surface-induced platelet activation by nitric oxide', ASAIO Journal, vol. 41, no. 3.
Sly MK, Prager MD, Eberhart RC, Jessen ME, Kulkarni PV. Inhibition of surface-induced platelet activation by nitric oxide. ASAIO Journal. 1995;41(3).
Sly, M. K. ; Prager, M. D. ; Eberhart, R. C. ; Jessen, Michael E ; Kulkarni, Padmakar V. / Inhibition of surface-induced platelet activation by nitric oxide. In: ASAIO Journal. 1995 ; Vol. 41, No. 3.
@article{3545fa7153324ea7a36c50e28620c9ec,
title = "Inhibition of surface-induced platelet activation by nitric oxide",
abstract = "This study was undertaken to determine whether the nitric oxide/platelet cyclic guanosine monophosphate (NO/cGMP) pathway might be used to reduce platelet activation by artificial surfaces. Because serotonin release (SR) is a platelet activation indicator, rabbit platelets in their own plasma (PRP) were labeled with 3H-serotonin. Labeled PRP was incubated with glass beads for 5-10 min. at 37°C with gentle agitation, and SR was measured. PRP pretreatment with NO gas or nitroprusside + N-acetylcysteine inhibited SR 50{\%}. Dose response studies indicate the existence of an optimal NO concentration above which its inhibitory effect is diminished. The guanylate cyclase inhibitor methylene blue attenuates the NO effect, implicating cGMP in NO mediated inhibition of surface induced platelet activation. Adult pigs were supported on a membrane oxygenator in an in vitro model of cardiopulmonary bypass (CPB). Introduction of NO gas into the oxygenator sweep gas at 500 ppm reduced platelet adherence to the oxygenator surfaces, increased circulating platelet counts, and decreased the rate of platelet aggregation (whole blood impedance platelet aggregometry) compared with the results of the control animals. Indications of NO toxicity were seen when the NO flow rate was increased to 1,000 ppm. These studies support the hypothesis that NO reduces platelet activation by artificial surfaces in clinical devices.",
author = "Sly, {M. K.} and Prager, {M. D.} and Eberhart, {R. C.} and Jessen, {Michael E} and Kulkarni, {Padmakar V}",
year = "1995",
language = "English (US)",
volume = "41",
journal = "ASAIO Journal",
issn = "1058-2916",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Inhibition of surface-induced platelet activation by nitric oxide

AU - Sly, M. K.

AU - Prager, M. D.

AU - Eberhart, R. C.

AU - Jessen, Michael E

AU - Kulkarni, Padmakar V

PY - 1995

Y1 - 1995

N2 - This study was undertaken to determine whether the nitric oxide/platelet cyclic guanosine monophosphate (NO/cGMP) pathway might be used to reduce platelet activation by artificial surfaces. Because serotonin release (SR) is a platelet activation indicator, rabbit platelets in their own plasma (PRP) were labeled with 3H-serotonin. Labeled PRP was incubated with glass beads for 5-10 min. at 37°C with gentle agitation, and SR was measured. PRP pretreatment with NO gas or nitroprusside + N-acetylcysteine inhibited SR 50%. Dose response studies indicate the existence of an optimal NO concentration above which its inhibitory effect is diminished. The guanylate cyclase inhibitor methylene blue attenuates the NO effect, implicating cGMP in NO mediated inhibition of surface induced platelet activation. Adult pigs were supported on a membrane oxygenator in an in vitro model of cardiopulmonary bypass (CPB). Introduction of NO gas into the oxygenator sweep gas at 500 ppm reduced platelet adherence to the oxygenator surfaces, increased circulating platelet counts, and decreased the rate of platelet aggregation (whole blood impedance platelet aggregometry) compared with the results of the control animals. Indications of NO toxicity were seen when the NO flow rate was increased to 1,000 ppm. These studies support the hypothesis that NO reduces platelet activation by artificial surfaces in clinical devices.

AB - This study was undertaken to determine whether the nitric oxide/platelet cyclic guanosine monophosphate (NO/cGMP) pathway might be used to reduce platelet activation by artificial surfaces. Because serotonin release (SR) is a platelet activation indicator, rabbit platelets in their own plasma (PRP) were labeled with 3H-serotonin. Labeled PRP was incubated with glass beads for 5-10 min. at 37°C with gentle agitation, and SR was measured. PRP pretreatment with NO gas or nitroprusside + N-acetylcysteine inhibited SR 50%. Dose response studies indicate the existence of an optimal NO concentration above which its inhibitory effect is diminished. The guanylate cyclase inhibitor methylene blue attenuates the NO effect, implicating cGMP in NO mediated inhibition of surface induced platelet activation. Adult pigs were supported on a membrane oxygenator in an in vitro model of cardiopulmonary bypass (CPB). Introduction of NO gas into the oxygenator sweep gas at 500 ppm reduced platelet adherence to the oxygenator surfaces, increased circulating platelet counts, and decreased the rate of platelet aggregation (whole blood impedance platelet aggregometry) compared with the results of the control animals. Indications of NO toxicity were seen when the NO flow rate was increased to 1,000 ppm. These studies support the hypothesis that NO reduces platelet activation by artificial surfaces in clinical devices.

UR - http://www.scopus.com/inward/record.url?scp=0028827399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028827399&partnerID=8YFLogxK

M3 - Article

C2 - 8573832

AN - SCOPUS:0028827399

VL - 41

JO - ASAIO Journal

JF - ASAIO Journal

SN - 1058-2916

IS - 3

ER -